U.S. FDA Approves Kite's Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Biotech Investing
European Medicines Agency Validates Bristol Myers Squibb's Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma Biotech Investing
European Medicines Agency Validates Bristol Myers Squibb's Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Biotech Investing
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma Biotech Investing
AbbVie Presents Late-Breaking Data on Risankizumab in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology Congress Biotech Investing
Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases Biotech Investing
AbbVie Presents New Analyses Evaluating RINVOQ® in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress Biotech Investing
FDA Approves QULIPTA , the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine Biotech Investing
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization Biotech Investing
